Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Montalescot, S. Wiviott, E. Braunwald, S. Murphy, C. Gibson, C. Mccabe, E. Antman (2009)
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trialThe Lancet, 373
M. Hasegawa, A. Sugidachi, T. Ogawa, T. Isobe, J. Jakubowski, F. Asai (2005)
Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (Prasugrel, LY640315), a novel P2Y12 receptor inhibitorThrombosis and Haemostasis, 94
R. Wright, Jeffrey Anderson, V. Chair, C. Adams, C. Bridges, D. Casey, S. Ettinger, F. Fesmire, T. Ganiats, H. Jneid, A. Lincoff, E. Peterson, G. Philippides, P. Théroux, N. Wenger, J. Zidar, E. Antman, R. Califf, W. Chavey, J. Hochman, T. Levin (2011)
2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesCirculation, 123
M. O’Donoghue, E.M. Antman, E. Braunwald (2009)
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysisJ Am Coll Cardiol, 54
M.J. Sorich, A. Vitry, M.B. Ward (2010)
Prasugrel vsclopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost, 8
J.E. Tcheng, S.M. Mackay (2012)
Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patientsAm J Cardiovasc Drugs, 12
S. Wiviott, D. Trenk, A. Frelinger, M. O’Donoghue, F. Neumann, A. Michelson, D. Angiolillo, H. Hod, G. Montalescot, Debra Miller, J. Jakubowski, Richard Cairns, S. Murphy, C. Mccabe, E. Antman, E. Braunwald (2007)
Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 TrialCirculation, 116
W. Hillegass, B. Brott, James Dobbs, S. Papapietro, V. Misra, G. Zoghbi (2011)
Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overviewVascular Health and Risk Management, 7
G. Montalescot, G. Sideris, R. Cohen, C. Meuleman, C. Sollier, O. Barthelemy, P. Henry, P. Lim, F. Beygui, J. Collet, D. Marshall, Junxiang Luo, Helene Petitjean, L. Drouet (2009)
Prasugrel compared with high-dose clopidogrel in acute coronary syndromeThrombosis and Haemostasis, 103
S. Murphy, E. Antman, S. Wiviott, G. Weerakkody, G. Morocutti, K. Huber, J. López-Sendón, C. Mccabe, E. Braunwald (2008)
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trialEuropean Heart Journal, 29
G. Montalescot, G. Sideris, R. Cohen (2010)
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome: the randomised, double-blind ACAPULCO studyThromb Haemost, 103
J. Mega, S. Close, S. Wiviott, Lei-Bin Shen, J. Walker, T. Simon, E. Antman, E. Braunwald, M. Sabatine (2010)
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysisThe Lancet, 376
C. Chin, M. Roe, K. Fox, D. Prabhakaran, D. Marshall, Helene Petitjean, Y. Lokhnygina, E. Brown, P. Armstrong, H. White, E. Ohman (2010)
Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trialAmerican heart journal, 160 1
D. Fintel (2012)
Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment optionsVascular Health and Risk Management, 8
K. Thygesen, J.S. Alpert, H.D. White (2007)
Universal definition of myocardial infarctionEur Heart J, 28
D. Angiolillo, J. Saucedo, R. deRaad, A. Frelinger, P. Gurbel, T. Costigan, J. Jakubowski, C. Ojeh, M. Effron (2010)
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study.Journal of the American College of Cardiology, 56 13
Yuri Pride, S. Wiviott, Jacqueline Buros, C. Zorkun, M. Tariq, E. Antman, E. Braunwald, C. Gibson (2009)
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in MyoAmerican heart journal, 158 3
D. Small, N. Farid, C. Payne, C. Konkoy, J. Jakubowski, K. Winters, D. Salazar (2010)
Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of PrasugrelClinical Pharmacokinetics, 49
E. Antman, S. Wiviott, S. Murphy, J. Voitk, Y. Hasin, P. Widimsky, H. Chandna, W. Macias, C. Mccabe, E. Braunwald (2008)
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.Journal of the American College of Cardiology, 51 21
S. Wiviott, E. Braunwald, C. Mccabe, I. Horváth, M. Keltai, J. Herrman, F. Werf, William Downey, B. Scirica, S. Murphy, E. Antman (2008)
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trialThe Lancet, 371
J. Tcheng, S. Mackay (2012)
Prasugrel versus Clopidogrel Antiplatelet Therapy after Acute Coronary SyndromeAmerican Journal of Cardiovascular Drugs, 12
D. Angiolillo (2009)
Variability in responsiveness to oral antiplatelet therapy.The American journal of cardiology, 103 3 Suppl
(2000)
ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 51 4
S. Wiviott, E. Braunwald, C. Mccabe, G. Montalescot, W. Rużyłło, S. Gottlieb, F. Neumann, D. Ardissino, Stefano Servi, S. Murphy, J. Riesmeyer, G. Weerakkody, M. Gibson, E. Antman (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 357 20
J. Mauskopf, J. Graham, J. Bae, K. Ramaswamy, A. Zagar, E. Magnuson, D. Cohen, E. Meadows (2012)
Cost-effectiveness of prasugrel in a US managed care populationJournal of Medical Economics, 15
E. Mahoney, Kaijun Wang, S. Arnold, I. Proskorovsky, S. Wiviott, E. Antman, E. Braunwald, D. Cohen (2010)
Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction TRICirculation, 121
J. Augoustides, Insung Chung (2009)
Faculty Opinions recommendation of Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction
P. Vandvik, A. Lincoff, Joel Gore, D. Gutterman, Frank Sonnenberg, P. Alonso-Coello, E. Akl, M. Lansberg, Gordon Guyatt, Frederick Spencer (2012)
Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest, 141 2 Suppl
M. Sorich, Agnes Vitry, Michael Ward, John Horowitz, Ross McKinnon (2010)
Prasugrel vs. clopidogrel for cytochrome P450 2C19‐genotyped subgroups: integration of the TRITON‐TIMI 38 trial dataJournal of Thrombosis and Haemostasis, 8
F. Mangiacapra, E. Barbato (2010)
Individual Variability of Response to Antiplatelet Therapy is an Important Determinant of Adverse Clinical OutcomeHigh Blood Pressure & Cardiovascular Prevention, 17
S. Wiviott, N. Desai, S. Murphy, G. Musumeci, M. Ragosta, E. Antman, E. Braunwald (2011)
Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.The American journal of cardiology, 108 7
D.A. Morrow, S.D. Wiviott, H.D. White (2009)
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarctionCirculation, 119
Y.B. Pride, S.D. Wiviott, J.L. Buros (2009)
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudyAm Heart J, 158
G. Biondi-Zoccai, M. Lotrionte, P. Agostoni, A. Abbate, E. Romagnoli, G. Sangiorgi, D. Angiolillo, M. Valgimigli, L. Testa, F. Gaita, I. Sheiban (2011)
Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes.International journal of cardiology, 150 3
S.D. Wiviott, E. Braunwald, D.J. Angiolillo (2008)
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38Circulation, 118
W. Hochholzer, S. Wiviott, E. Antman, C. Contant, Jianping Guo, R. Giugliano, A. Dalby, G. Montalescot, E. Braunwald (2011)
Predictors of Bleeding and Time Dependence of Association of Bleeding With Mortality: Insights From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel—Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38)Circulation, 123
Oral prasugrel (Effient®; Efient®) provides rapid, potent inhibition of platelet aggregation. It is indicated (in combination with aspirin) for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). In the pivotal clinical trial in this patient population, prasugrel-based therapy was associated with a significantly lower incidence of ischemic events than clopidogrel-based therapy. However, the efficacy of prasugrel was offset by a higher risk of bleeding than clopidogrel, with patients aged ≥75 years, those weighing <60 kg and those with a history of stroke or transient ischemic attack at the greatest risk. Prasugrel appears to have an overall favorable risk: benefit ratio in ACS patients undergoing PCI who do not have these three easily identifiable clinical characteristics. Limited pharmacoeconomic analyses suggest that prasugrel-based therapy is an economically attractive treatment strategy relative to clopidogrel-based therapy from a US healthcare payer perspective.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Dec 12, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.